Twelve-Month Outcomes of Standalone iStent Infinite in Primary Open-Angle Glaucoma
Journal of Clinical Medicine · 29.05.2026 · 15 (11) · 4215
DOI: 10.3390/jcm15114215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 29.05.2026. Verfasst von Arkadiy Yadgarov und 2 weiteren Autor:innen. Beteiligte Einrichtung: OMNI Eye Services, Atlanta, GA 30342, USA. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Glaukos (United States), Glaukos Corporation.
Abstract (Originalsprache)
Background/Objectives: Evaluation of real-world outcomes of standalone implantation of the third-generation trabecular micro-bypass device (iStent infinite) in eyes with mild to severe primary open-angle glaucoma (POAG). Materials: This retrospective, uncontrolled consecutive case series included eyes undergoing standalone iStent infinite implantation at a single U.S. practice. Outcomes were assessed through 12 months, including changes in intraocular pressure (IOP) and medication burden (primary), proportions achieving IOP ≤ 12/15/18 mmHg and medication categories (secondary), and safety. Subgroup analyses were completed based on preoperative IOP, glaucoma severity, and medication burden.
Results
Fifty-one eyes (mean age 66.5 ± 10.8 years) were included. Mean baseline IOP was 20.1 ± 5.4 mmHg on 2.1 ± 1.2 medications. At month 12, the mean IOP decreased to 16.0 ± 3.6 mmHg (−4.1 mmHg, −20.4%; p < 0.001), and mean medications decreased to 1.5 ± 1.2 (−28.6%; p < 0.001). The proportion of eyes achieving IOP ≤ 18/15/12 mmHg increased from 41.2%/15.7%/3.9% to 79.6%/42.9%/16.3%, respectively (all p < 0.001). Medication-free eyes increased from 15.7% to 30.6%, while eyes requiring ≥ 3 medications decreased from 47.1% to 20.4%. Eyes with baseline IOP > 18 mmHg achieved greater IOP reduction (−27.8%), whereas eyes with baseline IOP ≤ 18 mmHg maintained stable IOP with reduced medications. Kaplan–Meier analysis demonstrated 12-month freedom from incisional reintervention of 92.2%. No intraoperative complications occurred. Transient self-resolving hyphema was observed in 3.9% of eyes. A secondary incisional surgery was performed in four eyes (7.8%); no vision-threatening complications were reported.
Conclusions
Standalone iStent infinite implantation resulted in significant IOP and medication reductions with a favorable safety profile over 12 months, with outcomes aligned with preoperative treatment goals. These results suggest potential benefit as a less invasive real-world glaucoma intervention, warranting confirmation in larger prospective studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- OMNI Eye Services, Atlanta, GA 30342, USA.
- Glaukos Corporation, 1 Glaukos Way, Aliso Viejo, CA 92656, USA.
ORCID-Profile: Arkadiy Yadgarov, Dana M Hornbeak, Deana Davidova
Förderung
- Glaukos (United States)
- Glaukos Corporation
Zitieren
APA
Yadgarov, A., Hornbeak, D. M., & Davidova, D. (2026). Twelve-Month Outcomes of Standalone iStent Infinite in Primary Open-Angle Glaucoma. Journal of Clinical Medicine, 15(11), 4215. https://doi.org/10.3390/jcm15114215
Vancouver
Yadgarov A, Hornbeak DM, Davidova D. Twelve-Month Outcomes of Standalone iStent Infinite in Primary Open-Angle Glaucoma. Journal of Clinical Medicine. 2026;15(11):4215. doi:10.3390/jcm15114215
BibTeX
@article{Yadgarov2026,
author = {Yadgarov, Arkadiy and Hornbeak, Dana M and Davidova, Deana},
title = {Twelve-Month Outcomes of Standalone iStent Infinite in Primary Open-Angle Glaucoma},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {11},
pages = {4215},
doi = {10.3390/jcm15114215}
}
EUVIMED